International Clinical Trial: Single-Arm, Phase II Clinical Study of Ipalolimab and Tovorelimab in Combination with Regorafenib and Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (G/GEJ) Adenocarcinoma

Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600120217) titled 'Single-Arm, Phase II Clinical Study of Ipalolimab and Tovorelimab in Combination with Regorafenib and Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (G/GEJ) Adenocarcinoma' on March 11.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University)

Condition: locally advanced or metastatic gastric/gastroesophageal junction (G/GEJ) adenocarcinoma.

Intervention: Trial group:Iparomlimab and Tuvonralimab in Combination with Regorafenib and Chemotherap...